Radiosurgery and Fractionated Stereotactic Radiotherapy in Oligometastatic/Oligoprogressive Non-small Cell Lung Cancer patients: results of a multi-institutional series of 198 patients treated with “curative” intent

Treatment of stage IV Non Small Cell Lung Cancer (NSCLC) is rapidly evolving. Systemic chemotherapy, targeted therapy or immunotherapy represent the standard of care, depending on both disease biology and patient ’s characteristics. Results in terms of progression free survival (PFS) and overall survival (OS) range between 3-13 months and 5-25 months, respectively. [1–12]

Source: Lung Cancer - January 4, 2020 Category: Cancer & Oncology Authors: Michela Buglione, Barbara Alicja Jereczek-Fossa, Marco Lorenzo Bon ù, Davide Franceschini, Andrei Fodor, Isa Bossi Zanetti, Marianna Alessandra Gerardi, Paolo Borghetti, Davide Tomasini, Nadia Gisella Di Muzio, Olga Oneta, Marta Scorsetti, Ciro Franzese, Source Type: research